CAR-T Pipeline Summary

DelveInsight’s, “CAR-T Pipeline Insight, 2026” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in CAR-T pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

CAR-T Disease Understanding

CAR-T Overview

Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a transformative personalized immunotherapy that genetically engineers a patient's T cells to recognize and eliminate cancer cells with high specificity. Despite its remarkable clinical success, particularly in hematological malignancies, CAR-T therapy faces several challenges, including antigen heterogeneity, tumor immune evasion, treatment resistance, limited efficacy in solid tumors, and safety concerns such as cytokine release syndrome (CRS). Ongoing advances in target selection, CAR design, dosing strategies, and combination approaches are aimed at overcoming these limitations and improving therapeutic outcomes. As research continues to evolve, CAR-T therapy is expected to play an increasingly important role in precision oncology, with expanding clinical applications and continued innovation in next-generation CAR-T technologies.

 

Chimeric antigen receptor T (CAR-T) cells are genetically engineered T lymphocytes designed to recognize and eliminate cancer cells through the expression of a synthetic chimeric antigen receptor (CAR). The CAR consists of an extracellular antigen-binding domain, typically a single-chain variable fragment (scFv), which specifically recognizes tumor-associated antigens, and an intracellular signaling domain that activates T-cell proliferation, persistence, and cytotoxicity. Co-stimulatory molecules, such as CD28, 4-1BB, and OX40, further enhance CAR-T cell function, survival, and antitumor activity. CAR constructs have evolved substantially over time, from first-generation receptors containing only a CD3? signaling domain to advanced second-, third-, and fourth-generation designs incorporating additional co-stimulatory domains and cytokine-secreting modules to improve efficacy, durability, and immune activation. Recent innovations also focus on optimizing antigen specificity, reducing off-target toxicity, enhancing memory T-cell formation, and overcoming tumor resistance, thereby improving the overall safety and therapeutic potential of next-generation CAR-T cell therapies.

The therapeutic efficacy of CAR-T cell therapy largely depends on the selection of an appropriate target antigen, which is ideally highly expressed on tumor cells while exhibiting minimal expression on healthy tissues. CAR-T cells recognize these tumor-specific or tumor-associated antigens through a single-chain variable fragment (scFv), triggering activation of intracellular signaling domains such as CD3? and initiating a potent antitumor immune response. Once activated, CAR-T cells eliminate cancer cells through multiple mechanisms, including the release of cytotoxic molecules that induce tumor cell apoptosis, secretion of pro-inflammatory cytokines that amplify the immune response, and recruitment of other immune cells, such as natural killer cells and macrophages, to enhance coordinated tumor destruction. This targeted mechanism enables CAR-T therapy to deliver highly specific and effective anticancer activity while minimizing damage to normal tissues.

Despite its transformative clinical potential, CAR-T cell therapy is associated with several safety concerns and therapeutic challenges that may limit its broader application. The most common adverse event is cytokine release syndrome (CRS), a systemic inflammatory response that can range from mild flu-like symptoms to life-threatening complications, while other toxicities include neurotoxicity, prolonged cytopenias, immunosuppression, infections, and on-target off-tumor effects. Therapeutic efficacy is further challenged by tumor antigen heterogeneity, antigen loss, low antigen density, immune escape, treatment resistance, and the immunosuppressive tumor microenvironment, particularly in solid tumors, which restrict CAR-T cell infiltration and persistence. To address these limitations, next-generation CAR-T strategies are being developed, including multi-antigen targeting, switchable activation systems, optimized co-stimulatory domains such as 4-1BB (BB?), CD28, CD27, and OX40, and advanced CAR designs that enhance T-cell persistence, memory formation, antitumor activity, and long-term clinical responses while improving overall safety and durability of treatment.

Although CAR-T cell therapy is currently established primarily for the treatment of hematological malignancies, ongoing research is focused on expanding its application to a broader range of cancers while improving efficacy, safety, durability, and accessibility. Emerging strategies include the development of controllable CAR-T systems, multi-antigen and bispecific CAR constructs to overcome tumor heterogeneity and immune escape, and gene-editing technologies to enhance T-cell persistence and antitumor activity. Alternative immune cell platforms, such as chimeric antigen receptor natural killer (CAR-NK) cells, are also being explored for their potential to provide effective tumor targeting with an improved safety profile. Additionally, novel approaches aimed at overcoming the immunosuppressive tumor microenvironment are being investigated to enhance CAR-T cell survival and function. Continued advances in cellular engineering and immunotherapy are expected to broaden the clinical utility of CAR-based therapies and further establish their role in precision cancer treatment.

The first CAR-T cell therapy approved by the U.S. Food and Drug Administration (FDA) was tisagenlecleucel in 2017, initially for pediatric and young adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, with subsequent approvals for certain relapsed or refractory large B-cell lymphomas. Later the same year, axicabtagene ciloleucel received FDA approval for the treatment of adults with relapsed or refractory large B-cell lymphomas following multiple lines of systemic therapy. Since these landmark approvals, CAR-T cell therapy has become an established treatment option for several hematologic malignancies, while ongoing clinical trials continue to evaluate its potential across a broad range of cancers, including multiple myeloma, central nervous system tumors, hepatocellular carcinoma, and lung cancer.

"CAR-T Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the CAR-T pipeline landscape is provided which includes the disease overview and CAR-T treatment guidelines. The assessment part of the report embraces, in depth CAR-T commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, CAR-T collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

CAR-T Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence CAR-T R&D. The therapies under development are focused on novel approaches to treat/improve CAR-T.

CAR-T Emerging Drugs Chapters

This segment of the CAR-T report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

CAR-T Emerging Drugs

Descartes-08: Cartesian Therapeutics

Descartes-08 is an mRNA-modified, autologous CAR T-cell product directed against B-Cell Maturation Antigen (BCMA) that utilizes a novel modality and mechanism of action for treating gMG and other autoimmune diseases. Descartes-08 differs from anti-B-cell agents, which do not address long-lived plasma cells, and differs from FcRn blockers or complement inhibitors, which attempt to intervene only after autoantibodies are produced and pathogenic mediators are amplified. Descartes-08 is intended to halt production of autoantibodies by targeting pathogenic long-lived plasma cells with the potential to survive for decades within the body. Currently, the drug is in the Phase III stage of its development for the treatment of Myasthenia gravis (gMG).

Zola-cel: Bristol-Myers Squibb

Zola-cel (zolacabtagene autoleucel) is an investigational autologous CD19-directed CAR-T cell therapy being developed by Bristol Myers Squibb for the treatment of severe autoimmune diseases rather than cancer. It is designed to selectively eliminate CD19-positive B cells, which are key drivers of autoantibody production, with the goal of achieving an "immune reset" after a single infusion. Early clinical studies have demonstrated encouraging efficacy and a manageable safety profile, with durable disease control observed in patients with refractory autoimmune disorders. Bristol Myers Squibb is currently evaluating zola-cel across multiple indications, including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), multiple sclerosis (MS), myasthenia gravis (MG), and idiopathic inflammatory myopathies (IIM). Currently the drug is in Phase III stage of its development for the treatment of Systemic scleroderma.

CABA-201: Cabaletta Bio

CABA-201 is an investigational autologous CD19-directed CAR-T cell therapy developed by Cabaletta Bio for the treatment of B cell-mediated autoimmune diseases. The therapy incorporates a fully human CD19-binding domain and a 4-1BB co-stimulatory domain, enabling deep but transient depletion of CD19-positive B cells following a single infusion. This approach is designed to achieve an "immune system reset," with the goal of inducing durable, drug-free remission without the need for chronic immunosuppressive therapy. CABA-201 is currently being evaluated in the RESET™ clinical development program across multiple autoimmune indications, including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathies (myositis), generalized myasthenia gravis (gMG), and pemphigus vulgaris (PV). Early clinical data have demonstrated encouraging B-cell depletion, initial signs of clinical efficacy, and a manageable safety profile, supporting its potential as a disease-modifying, one-time cellular therapy for autoimmune disorders. Currently the drug is in Phase II/III stage of its development for the treatment of Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy.

FT819: Fate Therapeutics

FT819 is an investigational off-the-shelf, induced pluripotent stem cell (iPSC)-derived CD19-targeted CAR-T cell therapy developed by Fate Therapeutics for the treatment of B cell-mediated autoimmune diseases. Unlike conventional autologous CAR-T therapies, FT819 is manufactured from a clonal iPSC master cell bank, enabling standardized, readily available treatment without the need for patient-specific cell manufacturing. The therapy incorporates a 1XX CAR targeting CD19, which is designed to provide potent and sustained B-cell depletion while improving safety and T-cell persistence. FT819 is currently being evaluated in clinical trials for systemic lupus erythematosus (SLE), lupus nephritis (LN), systemic sclerosis (SSc), ANCA-associated vasculitis (AAV), and idiopathic inflammatory myopathies (IIM). Early clinical data have demonstrated encouraging efficacy, effective B-cell depletion, and a favorable safety profile, supporting its potential as a scalable next-generation CAR-T therapy for autoimmune diseases. But currently the therapy is in Phase II which is the highest stage of its development for the treatment of systemic lupus erythematosus and lupus nephritis.

ALLO-501A: Allogene Therapeutics

ALLO-501A is an investigational allogeneic, off-the-shelf CD19-targeted CAR-T cell therapy developed by Allogene Therapeutics for the treatment of relapsed or refractory large B-cell lymphoma (LBCL). Clinical studies have demonstrated encouraging efficacy, durable responses, and a manageable safety profile, supporting its potential as a readily available alternative to autologous CAR-T therapies. Currently, the drug is in Phase II stage of its development for the treatment of Diffuse large B cell lymphoma.

CTX112: CRISPR Therapeutics

CTX112 is an investigational allogeneic, off-the-shelf CD19-targeted CAR-T cell therapy developed by CRISPR Therapeutics for the treatment of B-cell malignancies. Manufactured from healthy donor T cells using CRISPR/Cas9 gene-editing technology, CTX112 is designed to enhance persistence, improve antitumor activity, and reduce the risk of graft-versus-host disease. The therapy is currently being evaluated in clinical trials for relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early data demonstrating encouraging clinical activity and a manageable safety profile. Currently, the drug is in Phase I/II stage of its development for the treatment of Relapsed/Refractory Hematologic Autoimmune Disease.

CT1190B: CARSGEN Therapeutics

CT1190B is an investigational autologous CD19-targeted CAR-T cell therapy developed by CARsgen Therapeutics for the treatment of B-cell malignancies, particularly relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). The therapy is engineered to selectively eliminate CD19-positive malignant B cells, with the goal of achieving durable clinical responses. Early clinical studies have demonstrated promising antitumor activity and a manageable safety profile, supporting its continued clinical development as a treatment option for patients with relapsed or refractory B-cell cancers. Currently, the drug is in Phase I stage of its development for the treatment of Systemic Lupus Erythematosus (SLE).

AUTO-8: Autolus Therapeutics

AUTO8 is an investigational dual-targeted autologous CAR-T cell therapy developed by Autolus Therapeutics for the treatment of relapsed or refractory multiple myeloma. The therapy combines an optimized BCMA-targeting CAR with Autolus' fast off-rate CD19 CAR (obe-cel) to enhance tumor cell killing, improve treatment durability, and reduce antigen escape. AUTO8 is currently being evaluated in a Phase I clinical trial, with early results demonstrating encouraging clinical activity, durable responses, and a favorable safety profile.

Further product details are provided in the report...

CAR-T Therapeutic Assessment

This segment of the report provides insights about the different CAR-T drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in CAR-T

There are approx. 180+ key companies which are developing the therapies for CAR-T. The companies which have their CAR-T drug candidates in the most advanced stage, i.e. Phase III include, Cartesian Therapeutics.

CAR-T Pipeline Drug Phases

DelveInsight’s report covers around 200+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

CAR-T Drugs Route of Administration

CAR-T pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

CAR-T Drugs Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

CAR-T Pipeline Product Type

• Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

CAR-T Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses CAR-T therapeutic drugs key players involved in developing key drugs.

CAR-T Clinical Trails and Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CAR-T drugs.

CAR-T Pipeline Report Insights

• CAR-T Pipeline Analysis
• CAR-T Therapeutic Assessment
• CAR-T Unmet Needs
• Impact of CAR-T Drugs

CAR-T Pipeline Report Assessment

• CAR-T Pipeline Product Profiles
• CAR-T Therapeutic Assessment
• CAR-T Pipeline Assessment
• Inactive drugs assessment
• CAR-T Unmet Needs

Key Questions Answered in the CAR-T Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing CAR-T drugs?
• How many CAR-T drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of CAR-T?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the CAR-T therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for CAR-T and their status?
• What are the key designations that have been granted to the emerging drugs?

Key CAR-T Companies

• Cartesian Therapeutics
• Bristol-Myers Squibb
• Cabaletta Bio
• Fate Therapeutics
• Allogene Therapeutics
• CRISPR Therapeutics
• Autolus Therapeutics
• CARSGEN Therapeutics
• Adicet Bio
• Regeneron
• Miltenyibiomedicine
• TriArm Therapeutics (Taiwan) Limited
• PeproMene Bio, Inc.
• Hebei Senlang Biotechnology Inc., Ltd.
• Allotera Therapeutics
• Takara Bio
• Immunotech Biopharma
• Chongqing Precision Biotech Co., Ltd
• Elicera
• Pepromene Bio
• Tempest Therapeutics
• Eutelix
• Precigen, Inc
• Mustang Bio
• Biontech
• Sana Biotechnology
• Immix Biopharma
• Kyverna Therapeutics
• Allotera Therapeutics
• TC BioPharm

Key CAR-T Pipeline Drugs

• Descartes-08
• Zola-cel
• CABA-201
• FT819
• ALLO-501A
• ALLO-329
• CTX112
• AUTO-8
• CT1190B
• Prulacabtagene leucel
• MB-CART19.1
• ARM011
• BAFFR-CAR T cells
• S1904 CD19 CAR-T
• WU-CART-007
• TBI-1501
• CAR-T-19 cell injection
• MC-1-50
• ELC-301
• ELC-401
• PMB-101
• PMB-102
• TPST-4003
• TPST-2003
• EU301
• EU307
• PRGN-3006
• PRGN-3005
• PRGN-3007
• MB-101
• BNT211
• SG293
• NXC-201
• KYV-102
• Sofi-cel
• TCB-003